People: Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

2.37USD
9 Feb 2010
Price Change (% chg)

$0.01 (+0.42%)
Prev Close
$2.37
Open
--
Day's High
$2.41
Day's Low
$2.34
Volume
68,616
Avg. Vol
179,842
52-wk High
$4.25
52-wk Low
$1.94

view people for:

Summary

Name Age Since Current Position
Mollica, Joseph 68 1998 Chairman of the Board
Gorman, Kevin 51 2008 President, Chief Executive Officer, Director
Coughlin, Timothy 42 2006 Chief Financial Officer, Vice President
Valeur-Jensen, Margaret 52 2005 Executive Vice President, General Counsel, Corporate Secretary
Bozigian, Haig 51 2008 Senior Vice President - Pharmaceutical and Preclinical Development
Grigoriadis, Dimitri 51 2008 Vice President - Research
O'Brien, Christopher 52 2007 Vice President and Chief Medical Officer
Lyons, Gary 58 2008 Director
Sherwin, Stephen 60 1999 Director
Pops, Richard 47 1998 Director
Vale, Wylie 67 1992 Director
Mitchell, W. Thomas 63 2002 Director
Lyle, Corinne 49 2004 Director
Rastetter, William 61 2010 Director
» Insider Trading

Biographies

Name Description
Mollica, Joseph Joseph A. Mollica, Ph.D. has served as a Chairman of the Board of Neurocrine Biosciences, Inc, since June 1997 and became Chairman of the Board in April 1998. Dr. Mollica is currently Chairman of the Board of Pharmacopeia Drug Discovery, Inc., a biopharmaceutical company focusing on drug discovery and development. From 1994 to 2004, Dr. Mollica served as the Chairman of the Board of Directors, President and Chief Executive Officer of Accelrys, the former parent of Pharmacopeia Drug Discovery. From 1987 to December 1993, Dr. Mollica served as Vice President, Medical Products of DuPont Company and then as President and CEO of DuPont Merck Pharmaceutical Company from 1991 to 1993. At Ciba-Geigy, where he was employed from 1966 to 1986, he served in a variety of positions of increasing responsibility, rising to Senior Vice President of Ciba-Geigy’s Pharmaceutical Division. He is currently on the boards of directors of Cytogen Corp., a biotechnology company focused on cancer diagnostics and therapeutics, and Pharmacopeia. He received his B.S. from the University of Rhode Island, his M.S. and Ph.D. from the University of Wisconsin and his Sc.D.h.c. from the University of Rhode Island.
Gorman, Kevin Kevin C. Gorman, Ph.D. is President, Chief Executive Officer and Director of Neurocrine Biosciences Inc. He has been employed with Neurocrine Biosciences since 1993. He is a founder of the Company and was appointed Executive Vice President and Chief Operating Officer in September 2006 after having served as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. Dr. Gorman is responsible for Research and Development, Business Development, Commercial Operations, and Marketing. From 1990 until 1993, Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Metra Biosystems, IDUN and ARIAD Pharmaceuticals. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
Coughlin, Timothy Timothy P. Coughlin was appointed Vice President and Chief Financial Officer of Neurocrine Biosciences in September 2006. After having served as Vice President, Controller. He is responsible for Accounting, Finance, Information Technology, and Investor Relations. Prior to joining Neurocrine in 2002, he was with CHI, a nationwide integrated healthcare delivery system where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP, and its predecessors, from 1989 to 1999. Mr. Coughlin holds a Bachelor’s degree in Accounting from Temple University and a Master’s degree in International Business from San Diego State University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.
Valeur-Jensen, Margaret Margaret E. Valeur-Jensen, J.D., Ph.D. became Executive Vice President, General Counsel and Corporate Secretary of Neurocrine Biosciences in February 2005. After having served as Senior Vice President, General Counsel and Corporate Secretary since January 2000. She joined the Company as Vice President, General Counsel and Secretary in October 1998. She is responsible for all corporate and patent law practices at the Company and serves as Corporate Secretary. From 1995 to 1998, Dr. Valeur-Jensen served as Associate General Counsel, Licensing and Business Law of Amgen. From 1991 to 1995, she served first as Corporate Counsel and later as Senior Counsel, Licensing for Amgen. Prior to joining Amgen, Dr. Valeur-Jensen practiced law at Davis, Polk & Wardell, a leading corporate law firm. She earned a J.D. degree from Stanford University, a Ph.D. in biochemistry and molecular biology from Syracuse University, and was a Post-Doctoral Fellow at Massachusetts General Hospital and Harvard Medical School.
Bozigian, Haig Haig P. Bozigian, Ph.D. was appointed Senior Vice President of Pharmaceutical and Preclinical Development of Neurocrine Biosciences, Inc. in December 2006 after having served as Vice President of Preclinical Development. He is responsible for all preclinical, chemical and pharmaceutical development. Dr. Bozigian joined Neurocrine in 1997. With extensive expertise in CNS related new product development, Dr. Bozigian has participated in research and development for more than 20 years. Prior to joining Neurocrine, Dr. Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals and as a Clinical Pharmacokineticist at GlaxoSmithKline. Dr. Bozigian earned his B.S. in Microbiology from the University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona.
Grigoriadis, Dimitri Dimitri E. Grigoriadis, Ph.D., became Vice President of Research in January 2007 and oversees all research functions including drug discovery, biology and chemistry. Dr. Grigoriadis joined Neurocrine in 1993, established the Pharmacology and drug screening groups and was most recently a Neurocrine Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine, he was a Senior Scientist in the Neuroscience group at the Du Pont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B.Sc. from the University of Guelph in Ontario Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990.
O'Brien, Christopher Christopher F. O'Brien, M.D. Senior Vice President and Chief Medical Officer of Neurocrine Biosciences, Inc. He became Chief Medical Officer in January 2007 after having served as Sr. Vice President of Clinical Development since 2005. He is responsible for Clinical Operations, Regulatory Affairs, Drug Safety, Biostatistics and Data Management. Prior to joining Neurocrine, he was Chief Medical Officer at Prestwick Pharmaceuticals from 2003 to 2005 and Senior Vice President of Global Medical Affairs at Elan Pharmaceuticals from 2000 to 2003. Dr. O’Brien is a Board Certified Neurologist and obtained his undergraduate degree in Neuroscience from Boston University, his medical degree and residency training from the University of Minnesota and fellowship training from the University of Rochester School of Medicine. In addition, Dr. O’Brien holds an appointment as Associate Professor (voluntary) in the Neuroscience Department at the University of California, San Diego.
Lyons, Gary Gary A. Lyons is Director of Neurocrine Biosciences Inc since February 1993. He has served as President, Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr. Lyons held a number of senior management positions at Genentech including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on immunology and Vical, Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.
Sherwin, Stephen Stephen A. Sherwin, M.D. was elected to the Board of Directors of Neurocrine Biosciences, Inc in April 1999. Since March 1990, Dr. Sherwin has served as Chief Executive Officer and Director of Cell Genesys, Inc., a biotechnology company. In March 1994, he was elected as Chairman of the Board of Cell Genesys. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., a biotechnology company, most recently as Vice President of Clinical Research. Prior to 1983, Dr. Sherwin held various positions on the staff of the National Cancer Institute. Dr. Sherwin also serves as Chairman of the Board of Ceregene, Inc., a biotechnology company he founded in 2001 focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders and a former subsidiary of Cell Genesys. Dr. Sherwin was also a co-founder of Abgenix, a company focused on the discovery, development and manufacture of human therapeutic antibodies, which was acquired by Amgen in 2006 and was a former subsidiary of Cell Genesys. Dr. Sherwin is a member of the Board of Directors of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for inflammatory diseases, cancer and viral diseases, and is also a director and treasurer of the Biotechnology Industry Organization. He holds a B.A. in biology from Yale and an M.D. from Harvard Medical School and is board-certified in internal medicine and medical oncology.
Pops, Richard Richard F. Pops was elected to the Board of Directors of Neurocrine Biosciences, Inc. in April 1998. Mr. Pops became Chairman of Alkermes, Inc. in April 2007. From February 1991 to April 2007, Mr. Pops had been Chief Executive Officer of Alkermes, Inc. Under his leadership, Alkermes has grown from a privately held company with 25 employees to a publicly traded pharmaceutical company with more than 500 employees in multiple locations in the United States. He currently serves on the Board of Directors of: Alkermes, Inc.; Reliant Pharmaceuticals, LLC, a cardiovascular pharmaceutical products company; CombinatoRx, Inc., a company focused on developing new medicines built from synergistic combinations of approved drugs; Acceleron Pharma, Inc., a biotechnology company focused on musculoskeletal and metabolic therapeutics; Sirtris Pharmaceuticals, Inc, a biotechnology company focused on discovering therapies to combat aging, metabolic and neurological diseases; Expressive Constructs, Inc., a biotechnology company engaged in research and development of new antibody detection technologies; the Biotechnology Industry Organization; the New England Healthcare Institute; Pharmaceutical Research and Manufacturers of America (PhRMA) and Harvard Medical School Board of Fellows. He received a B.A. in economics from Stanford University in 1983.
Vale, Wylie Wylie W. Vale, Ph.D. is Director of Neurocrine Biosciences, Inc. He is one of Company'stwo academic co-founders, Chief Scientific Advisor, Neuroendocrinology, and a member of the Company’s Founding Board of Scientific and Medical Advisors. Dr. Vale was elected a director of the Company in September 1992. He is The Helen McLoraine Professor of Molecular Neurobiology at The Salk Institute for Biological Studies and is the Senior Investigator and Head of The Clayton Foundation Laboratories for Peptide Biology at The Salk Institute, where he is a member of the Corporation and former member of the Board of Trustees and former Chairman of the Faculty. He is also an Adjunct Professor of Medicine at the University of California, San Diego. In addition, Dr. Vale is recognized for his work on the molecular, pharmacological and biomedical characterization of neuroendocrine peptides, growth factors and their receptors. In recognition of his discoveries, he has received numerous awards and he is a member of the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Sciences. Dr. Vale is a co-founder and member of the Board of Directors of Acceleron Pharma, Inc., a biotechnology company focused on musculoskeletal and metabolic therapeutics. He is a past President of both the American Endocrine Society and the International Society of Endocrinology. Dr. Vale received a B.A. in biology from Rice University and a Ph.D. in physiology and biochemistry from the Baylor College of Medicine.
Mitchell, W. Thomas W. Thomas Mitchell is Director of Neurocrine Biosciences, Inc since November 2002. He is the former Chairman of the Board and Chief Executive Officer of Genencor International, a biotechnology company. Under his guidance, Genencor’s revenues grew from under $30 million to over $325 million. In addition, he successfully managed the acquisition and integration of three major businesses to build the global enterprise that is now Genencor. An industry leader, Mr. Mitchell has participated in a number of important policy initiatives including the 1999 federal executive order that created the national bioenergy initiative. Mr. Mitchell also served as a member of the Governor’s Council on Biotechnology in California, which was responsible for helping to improve the state’s competitiveness in the mid-1990’s. Mr. Mitchell currently serves on the Board of Directors of DJO, Inc. a medical device company, where he is a member of the audit committee. He also served on the Advisory Boards of the Chemical Engineering School at Cornell University and the University of Iowa’s School of Engineering. He received his B.S. in chemical engineering from Drexel University. He also completed the Executive Development Program at the University of Michigan.
Lyle, Corinne Corinne H. Lyle was appointed Board of Directors of the Neurocrine Biosciences in June 2004. She is a Corporate Vice President of and the President of Global Operations for Edwards Lifesciences, a global leader in products and technologies to treat advanced cardiovascular disease and the leading heart valve company in the world. From 2003 to 2005, she served as Chief Financial Officer and Treasurer for Edwards. From October 1998 until February 2003, she served as Vice President, Chief Financial Officer of Tularik, Inc., a company involved in the discovery and development of drugs based on gene regulation. Prior to joining Tularik, she was Executive Director-Health Care Group at Warburg Dillon Read LLC, an investment bank. She currently serves on the Board of Directors and is a member of the audit committee of Onyx Pharmaceuticals, a biopharmaceutical company that develops small molecule cancer treatments. Ms. Lyle received her undergraduate degree in industrial engineering from Stanford University and her M.B.A. from Harvard Business School.
Rastetter, William Dr. William H. Rastetter Ph.D. has been appointed as the Director of Neurocrine Biosciences, Inc. He is currently the Chairman and Chief Executive Officer of Receptos, a privately-held drug discovery and development company. He is also currently the Chairman of the Board of Directors of Illumina, Inc., and is a partner in the venture capital firm Venrock. Dr. Rastetter retired as the Executive Chairman of Biogen Idec Inc., a biopharmaceutical company, at the end of 2005 and had served in that position since the November 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation. He served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003 and as chairman of the Board of Directors from May 1996 to November 2003. Additionally, he served as President of IDEC Pharmaceuticals from 1986 to 2002 and as Chief Financial Officer from 1988 to 1993. From 1982 to 1986 Dr. Rastetter served in various positions at Genentech, Inc., a biotechnology company, and prior to Genentech he was an associate professor at the Massachusetts Institute of Technology. He earned a Ph.D. from Harvard University in 1975. He also holds a Masters of Arts in Chemistry from Harvard University and a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology.

Basic Compensation

Name Fiscal Year Total
Mollica, Joseph --
Gorman, Kevin 1,519,490
Coughlin, Timothy 1,106,770
Valeur-Jensen, Margaret 1,350,780
Bozigian, Haig 770,132
Grigoriadis, Dimitri 874,949
O'Brien, Christopher 926,837
Lyons, Gary 1,273,650
Sherwin, Stephen --
Pops, Richard --
Vale, Wylie --
Mitchell, W. Thomas --
Lyle, Corinne --
Rastetter, William --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Mollica, Joseph 0 0
Gorman, Kevin 216,644 5,838,654
Coughlin, Timothy 6,000 159,000
Valeur-Jensen, Margaret 247,940 6,038,071
Bozigian, Haig 0 0
Grigoriadis, Dimitri 0 0
O'Brien, Christopher 0 0
Lyons, Gary 573,583 12,752,153
Sherwin, Stephen 0 0
Pops, Richard 0 0
Vale, Wylie 0 0
Mitchell, W. Thomas 0 0
Lyle, Corinne 0 0
Rastetter, William 0 0

Insider Trading

Name Shares Traded Price
GORMAN KEVIN CHARLES 9,445 $2.52
COUGHLIN TIMOTHY P 8,697 $2.52
VALEUR JENSEN MARGARET E 8,697 $2.52
BOZIGIAN HAIG P 751 $2.64
OBRIEN CHRISTOPHER FLINT 1,503 $2.65
GRIGORIADIS DIMITRI E 1,503 $2.67
MITCHELL W THOMAS 900 $2.17
OBRIEN CHRISTOPHER FLINT 4,859 $3.11
GRIGORIADIS DIMITRI E 3,038 $3.12
BOZIGIAN HAIG P 3,642 $3.11
GRIGORIADIS DIMITRI E 12,606 $3.43
GORMAN KEVIN CHARLES 15,146 $3.43
BOZIGIAN HAIG P 12,774 $3.43
VALEUR JENSEN MARGARET E 12,117 $3.43
OBRIEN CHRISTOPHER FLINT 12,151 $3.43
COUGHLIN TIMOTHY P 12,117 $3.43
BVF PARTNERS L P 6,000 $3.10
BVF PARTNERS L P 2,000 $3.10
BVF PARTNERS L P 1,000 $3.10
BVF PARTNERS L P 1,900 $3.10
BVF PARTNERS L P 4,000 $3.10
BVF PARTNERS L P 1,000 $3.10
BVF PARTNERS L P 15,000 $3.06
BVF PARTNERS L P 4,000 $3.06
BVF PARTNERS L P 6,200 $3.06
» Full list on Insider Trading
view people for: